Sight Sciences CFO Rodberg sells $25,670 in shares

CFO James Rodberg sold 7,231 shares of Sight Sciences (SGHT) on April 6, 2026 at a $3.55 weighted average for $25,670 to cover tax liabilities; he now directly owns 230,939 shares. Sight Sciences beat Q4 2025 expectations with EPS of -$0.08 vs -$0.15 forecast and revenue of $20.4M vs $20.17M, and the company won a patent lawsuit awarding $34M in damages ($5.5M lost profits, $28.5M royalties). William Blair reiterated an Outperform; the stock trades near a $3.40 fair value while remaining down 56% YTD but up 48% over 12 months.

Analysis

The recent legal outcome meaningfully de-risks Sight Sciences’ pathway to converting intellectual property into cash flows, shifting the investment question from binary litigation outcome to execution on licensing and commercialization. If management can convert an adverse ruling into recurring royalties or settlements within 6–18 months, a modest royalty stream (high-single to low-double-digit millions) rolled into an 8–12x valuation multiple would produce a non-trivial uplift to equity value for a company of this scale. That pathway is lumpy and timing-sensitive, so valuation upside is concentrated in the next 12 months conditional on visible licensing or settlement announcements.

Insider selling tied to compensation events is liquidity-driven and usually short-lived; however, concentrated RSU vesting can create discrete supply shocks on low-ADV days that exaggerate downside for momentum players. Trading volatility remains elevated, which favors option-structured exposure over outright equity for size-constrained allocators. On the competitive side, the ruling raises the cost of entry for large incumbents — expect direct product redesign spend and potential supply-chain requalification costs at competitors over the next 6–24 months, which could temporarily slow competitor rollouts and indirectly help adoption for the plaintiff’s install base.

Key risks are legal (appeal/stay), execution (commercialization of IP), and capital markets (continued low liquidity and headline-driven volatility). A successful appeal or a stay would likely unwind much of the re-rating quickly; conversely, a public licensing deal or renewed distributor traction would catalyze a >30% re-rate within 3–9 months. Monitor docket timing, RSU vesting windows, and any early-stage licensing term sheets as primary catalysts and drawdown triggers.

Key Decisions for Investors

• Initiate a tactical long in SGHT sized 0.01–0.03% NAV (~$1–3M) via two tranches: 50% on any 10–15% pullback from current levels and remainder on a confirmed licensing/settlement announcement within 6 months; use a 30% hard stop or purchase 9–12 month protective puts to cap downside — asymmetric target: 40–100% upside if royalties/settlements materialize, 1:1–1.5:1 downside risk to stop.
• Buy a time-limited, cost-controlled upside: purchase a 9–12 month SGHT call spread (long nearer-term ITM call, short higher strike OTM call) sized to equal 0.02% NAV — limits premium bleed while retaining 2–4x upside if positive commercial read-throughs occur; exit on 50% of max gain or on an adverse appellate ruling.
• Pair trade to neutralize market beta: go long SGHT and short ALC notional-equivalent (size balanced by dollar exposure) for a 3–12 month horizon to capture asymmetric re-rating of SGHT vs. legal/operational impairment at the competing incumbent; cut pair if appeal is stayed or if ALC makes a unilateral licensing settlement, re-evaluate on each legal filing.
• Event hedge: if initiating equity, sell near-term covered calls (6–9 weeks) against a portion of the position to monetize inflated implied vol ahead of expected RSU-related selling windows; redeploy premium to buy longer-dated protection or increase call-spread exposure upon volatility compression.